Affibody regains autoimmune asset, claims ex-partner Acelyrin unable ‘to fully capitalize’ on potential

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not been able to fully capitalize” on the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks